Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Johns Hopkins researchers identify 'missing culprit' in heart failure

20.03.2015

Drugs that block disease-fueling enzyme already tested for other conditions

Working with lab animals and human heart cells, scientists from Johns Hopkins and other institutions have identified what they describe as "the long-sought culprit" in the mystery behind a cell-signaling breakdown that triggers heart failure. The condition, which affects nearly 6 million Americans and 23 million people worldwide, is marked by progressive weakening and stiffening of the heart muscle and the organ's gradual loss of blood-pumping ability.


effects of pressure overload as seen in the image in the upper right corner. By contrast, mice with intact PDF-9 genes developed enlarged, dilated hearts captured here by walls that are stretched far apart from each other, as shown in the lower left corner.

Credit: Johns Hopkins Medicine

The research results, described March 18 in the journal Nature, reveal that an enzyme called PDE-9 interferes with the body's natural "braking" system needed to neutralize stress on the heart. The experiments demonstrate that the enzyme wreaks mischief by gobbling up a signaling molecule, cGMP, which normally stimulates the production of a heart-protective protein called PKG, known to shield the heart muscle from the ravages of disease-causing stress, such as long-standing high blood pressure.

Naturally found in the gut, kidneys and brain, PDE-9 is already a prime suspect in neurodegenerative conditions such as Alzheimer's, the researchers say. But the new study shows the enzyme's footprints are also present in heart cells and markedly elevated in patients with heart failure -- evidence that PDE-9 is a multitasking "offender" and a key instigator of heart muscle demise, the researchers say.

To understand the enzyme's role, the scientists exploited the knowledge that heart muscle health is safeguarded by two separate mechanisms, or signaling pathways. Activated by two different chemicals -- nitric oxide and natriuretic peptide -- each pathway produces cGMP, which in turn stimulates the all-important heart muscle protector PKG. Most cases of heart failure, the researchers say, are fueled by breakdowns in both.

"The existence of two separate pathways with overlapping but distinct functions is nature's insurance policy, a fail-safe redundancy to ensure that should one pathway falter, the other one can compensate and maintain heart muscle function," says senior investigator David Kass, M.D., professor of medicine at the Johns Hopkins University School of Medicine and its Heart and Vascular Institute.

Nearly a decade ago, a team led by Kass identified the culprit responsible for breakdown in one of the signaling pathways, an enzyme called PDE-5 -- also known to cause erectile dysfunction -- and ever since then scientists have searched for the second "offender" that causes glitches in the other pathway. The discovery of PDE-9 provides that long-sought "break in the case," the team says.

"Like a play with multiple characters, heart muscle function is the result of a complex but perfectly synchronized interaction of several proteins, enzymes and hormones," says lead investigator Dong Lee, M.S., Ph.D., a cardiology research associate at the Johns Hopkins University School of Medicine. "Our findings reveal that, like two subplots that converge in the end of the play, PDE-5 and PDE-9 are independent rogue operators, each leading to heart muscle damage but doing so through different means."

Kass' earlier studies showed that PDE-5, like its newly identified accomplice PDE-9, inflicts damage by feeding on heart-protective cGMP and PKG. But the new findings reveal an important difference -- PDE-9 has an appetite for the form of cGMP stimulated by the second signaling pathway.

In other words, Kass says, too much PDE-9 can interfere with the second of the two heart-protective systems by speeding up the breakdown of cGMP, which in turn reduces levels of PKG, rendering heart cells prone to malfunction and the heart muscle vulnerable to scarring and damage.

The research team also notes that heart failure treatments blocking the activity of PDE-9 may be right around the corner, with drugs that inhibit PDE-9 already being tested for use in people with Alzheimer's disease.

In the current study, such PDE-9 blockers not only stopped heart muscle enlargement and scarring in mice with heart failure, but they nearly reversed the effects of the disease.

"We believe the identification of PDE-9 puts us on the cusp of creating precision therapies that target the second pathway or developing combined therapies that avert glitches in both pathways," Kass says.

The new findings could be even more relevant for the nearly one-half of all heart failure patients with an especially recalcitrant form of the disease known as heart failure with preserved ejection fraction -- a treatment-defying condition in which the heart appears to pump normally but is, in fact, scarred and hardened. Heart cells obtained from people with this form of the disease showed PDE-9 levels six times higher than normal hearts, suggesting that people with that form of the disease have far less heart-protective PKG, the researchers note.

In one set of experiments, the researchers chemically stimulated human heart cells and cells from newborn mice to mimic the effects of heart failure. The cells ballooned beyond their normal size, but when treated a PDE-9 antidote, the cells returned to near normal.

In another test, the scientists created mice genetically incapable of making PDE-9 and compared their heart cells and overall organ function to mice with intact PDE-9 genes. The heart cells of mice lacking PDE-9 had higher cGMP levels than the cells of mice with intact PDE-9. Next, mice in both groups underwent surgical narrowing of the aorta, the body's main blood vessel, a procedure intended to create extra workload for the heart and induce heart failure. Mice lacking the PDE-9 gene fared much better. Their hearts had far less scarring, muscle thickening and dilation than the hearts of mice with intact PDE-9.

In a third experiment, the scientists divided mice with surgically induced heart failure into three groups. One group received treatment with a PDE-9 blocking drug, another was treated with the PDE-5 blocker sildenafil and a third was given placebo.

After four weeks of therapy, mice treated with placebo developed full-blown heart failure, while mice treated with either PDE-9 or PDE-5 blockers showed marked improvements in heart muscle function and size, their hearts' pumping ability reverting to near normal.

To compare the effects of PDE-5 and PDE-9 inhibitors on heart function, the researchers then fed half the mice with a chemical that turned off the heart-protective signaling pathway regulated by PDE-5. In that group, treatment with a PDE-5 inhibitor made no difference. However, when given a PDE-9 blocker, the animals' hearts showed notable improvement. This finding, the research team says, illustrates the notion that heart muscle failure is fueled by flaws in two separate signaling cascades, each one regulated by a different enzyme and benefiting from different treatment.

"In practical terms, this affirms that preserving the function in one pathway can avert clinical disease, even if the other one goes bad," Kass says.

###

The work was supported in part by the National Institutes of Health under grant numbers HL-119012, HL-093432, HL-089297 and HL-07227; Fondation Leducq TransAtlantic Network of Excellence; the Peter Belfer Laboratory Foundation; the Abraham and Virginia Weiss Professorship in Cardiology; the American Heart Association; and the Austrian Academy of Sciences. Drug manufacturer Pfizer provided the PDE-9 inhibitors and the genetically altered mice.

Other Johns Hopkins investigators involved in the study included Guangshuo Zhu, Manling Zhang, Thomas Danner, Peter P. Rainer, Djahida Bedja, Jonathan A. Kirk, Mark J. Ranek, Jennifer Van Eyk and Eiki Takimoto.

Other organizations participating in the research were the Cardiovascular Research Institute at VU University Medical Center in Amsterdam, Cedars-Sinai Medical Center in Los Angeles, Kangwon National University College of Medicine in South Korea, the University of Vermont and the Mitsubishi Tanabe Pharma Corporation of Japan.

Media Contact

Ekaterina Pesheva
epshev1@jhmi.edu
410-502-9433

 @HopkinsMedicine

http://www.hopkinsmedicine.org 

Ekaterina Pesheva | EurekAlert!

Further reports about: PKG cGMP enzyme function heart cells heart failure heart muscle muscle function

More articles from Health and Medicine:

nachricht Cholesterol-lowering drugs may fight infectious disease
22.08.2017 | Duke University

nachricht Once invincible superbug squashed by 'superteam' of antibiotics
22.08.2017 | University at Buffalo

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

Cholesterol-lowering drugs may fight infectious disease

22.08.2017 | Health and Medicine

Meter-sized single-crystal graphene growth becomes possible

22.08.2017 | Materials Sciences

Repairing damaged hearts with self-healing heart cells

22.08.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>